Bisdemethoxycurcumin-d8
CAT:
804-HY-N0007S-01
Size:
1 mg
For Laboratory Research Only. Not for Clinical or Personal Use.
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Bisdemethoxycurcumin-d8
UNSPSC Description:
Bisdemethoxycurcumin-d8 is the deuterium labeled Bisdemethoxycurcumin. Bisdemethoxycurcumin(Curcumin III; Didemethoxycurcumin) is a natural derivative of curcumin with anti-inflammatory and anti-cancer activities.Target Antigen:
Apoptosis; AutophagyType:
Isotope-Labeled CompoundsRelated Pathways:
Apoptosis;AutophagyField of Research:
CancerPurity:
98.0Solubility:
10 mM in DMSOSmiles:
O=C(CC(/C=C/C1=C([2H])C([2H])=C(O)C([2H])=C1[2H])=O)/C=C/C2=C([2H])C([2H])=C(O)C([2H])=C2[2H]Molecular Weight:
316.38References & Citations:
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Lee PJ, et al. Bisdemethoxycurcumin Induces Apoptosis in Activated Hepatic Stellate Cells via Cannabinoid Receptor 2. Molecules. 2015 Jan 14;20(1):1277-92.|[3]Chen J, et al. Natural borneol enhances bisdemethoxycurcumin-induced cell cycle arrest in the G2/M phase through up-regulation of intracellular ROS in HepG2 cells. Food Funct. 2014 Dec 24.|[4]Luo C, et al. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. Oncol Lett. 2015 Jan;9(1):270-274.|[5]Li YB, et al. Bisdemethoxycurcumin Increases Sirt1 to Antagonize t-BHP-Induced Premature Senescence in WI38 Fibroblast Cells. Evid Based Complement Alternat Med. 2013;2013:851714.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Clinical Information:
No Development ReportedCAS Number:
2470233-08-8